Thrombosis, a major cause of deaths in this modern era responsible for 31% of all global
deaths reported by WHO in 2017, is due to the aggregation of fibrin in blood vessels which …

Abstract Annexin A2 (ANXA2) is widely used as a marker in a variety of tumors. By
regulating multiple signal pathways, ANXA2 promotes the epithelial‐mesenchymal …

Stroke continues to be the third-leading cause of death and disability worldwide. The limited
availability of diagnostic tools approved therapeutics and biomarkers that help monitor …

Thrombolytic (clot-busting) therapies with plasminogen activators (PAs) are first-line
treatments against acute thrombosis and ischemic stroke. However, limitations such as …

The structural complexity of the brain hinders the traditional treatment of brain diseases from
achieving desirable outcomes, which urges the research and development of multiple …

The development of safe and efficacious enzyme-based human therapies has increased
greatly in the last decades, thanks to remarkable advances in the understanding of the …

Obstructive sleep apnoea (OSA) is a common disease which is characterised by repetitive
collapse of the upper airways during sleep resulting in chronic intermittent hypoxaemia and …

Background “Micro RNAs and their target genes recently have been identified to play a
crucial role in the molecular pathogenesis of post-stroke ischemic cellular injury, which …

Ischemic stroke (IS) is a central nervous system neurological disorder ascribed to an acute
focal trauma, with high mortality and disability, leading to a heavy burden on family and …

Polyphenolic compounds are a diverse collection of secondary metabolites. They are
present in nature and have potential therapeutic and medical value due to their anti …